MacroGenics Inc at Cowen HealthCare Conference Transcript
So thank you, Boris, for the invitation today. I'll be making forward-looking statements during the course of this presentation, so please refer to our SEC filings, understand the risks associated with investment in MacroGenics.
MacroGenics is the leader in development of antibody-based therapeutics for the treatment of cancer. We've built our company around 2 proprietary platforms, a bispecific DART platform that exploits multiple mechanisms of action and an Fc-engineering platform, which enhances innate and adaptive immunity. Our focus right now is to advance our very large clinical portfolio forward into late-stage development. We recently announced the filing of a BLA, and we have a PDUFA date in 2020 with our most advanced clinical program, and we anticipate 3 additional ongoing or anticipated registration-directed studies in the course of this and next year.
Our pipeline right now incorporates 7 clinical assets of which we retain major market opportunities for 6 of them.
Here's the listing of our end
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |